Janssen Reports First Results from Phase 2 SunRISe-1 Study of TAR-200 and Anti- PD-1 Antibody Cetrelimab in Patients with Bacillus Calmette-Guérin-Unresponsive Non-Muscle-Invasive Bladder Cancer

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the first results from the open-label Phase 2 SunRISe-1 study...

Related Keywords

United States ,Chicago ,Illinois ,America ,American ,Indianj Urol ,Obrian Kenney ,Siamak Daneshmand ,Cancer Treatment Centers Of America ,Janssen Biotech Inc ,Janssen Pharmaceutical Companies Of Johnson ,Johnson ,World Health Organization ,Exchange Commission ,American Urological Association Annual Meeting ,Janssen Pharmaceutical Companies ,Drug Administration ,Norris Comprehensive Cancer Center ,Companies Of Johnson ,None Of Janssen Research Development ,Janssen Research Development ,American Cancer Society ,Bacillus Calmette Gu ,Late Breaker Podium Presentation Session ,Urologic Oncology ,Keck School ,Southern California ,Christopher Cutie ,Vice President ,Disease Area Leader ,Bladder Cancer ,Janssen Research ,Janssen Oncology ,Pharmaceutical Companies ,Infectious Diseases ,Janssen Biotech ,Private Securities Litigation Reform Act ,Annual Report ,Note Regarding Forward Looking ,Quarterly Reports ,Published September ,Cancer Treatment Centers ,Accessed April ,High Risk Non Muscle Invasive Bladder ,Published January ,Med Sci ,American Cancer ,Accessed March ,Janssen Pharmaceutical Companies Of Johnson Amp ,Pharmaceuticals ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Clinical Trials Amp Medical Discoveries ,